(ALHC) Alignment Healthcare - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US01625V1044
Stock: Medicare Advantage, Health Plans, Care Delivery
Total Rating 53
Risk 39
Buy Signal 0.73
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.2% |
| Relative Tail Risk | -14.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.93 |
| Alpha | 33.78 |
| Character TTM | |
|---|---|
| Beta | 0.080 |
| Beta Downside | 0.081 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.80% |
| CAGR/Max DD | 0.42 |
Description: ALHC Alignment Healthcare January 12, 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) runs a senior-focused, consumer-centric healthcare platform in the United States, offering customized Medicare Advantage plans. Founded in 2013 and headquartered in Orange, California, the firm positions itself within the Health Care Services sub-industry.
As of Q3 2024, ALHC reported approximately 55,000 Medicare Advantage members, a 12% year-over-year increase, and generated $78 million in total revenue, reflecting a 9% operating margin. The company’s enrollment growth outpaced the industry average of ~5% YoY, suggesting effective member acquisition and retention strategies.
The senior-care market is being driven by two macro trends: (1) the U.S. population aged 65+ is projected to rise from 54 million in 2024 to 73 million by 2034, expanding the addressable pool for Medicare Advantage, and (2) CMS policy shifts toward value-based reimbursement are increasing the premium on cost-efficiency and care coordination-areas where ALHC’s platform claims a competitive edge.
For a deeper, data-rich perspective on ALHC’s valuation and risk profile, you might explore the analyst notes on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -20.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 42.60 > 1.0 |
| NWC/Revenue: 10.29% < 20% (prev 8.73%; Δ 1.56% < -1%) |
| CFO/TA 0.16 > 3% & CFO 181.6m > Net Income -20.8m |
| Net Debt (-288.4m) to EBITDA (29.0m): -9.94 < 3 |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (208.9m) vs 12m ago 9.18% < -2% |
| Gross Margin: 12.42% > 18% (prev 0.10%; Δ 1231 % > 0.5%) |
| Asset Turnover: 405.3% > 50% (prev 356.5%; Δ 48.82% > 0%) |
| Interest Coverage Ratio: -0.03 > 6 (EBITDA TTM 29.0m / Interest Expense TTM 17.3m) |
Altman Z'' -1.84
| A: 0.34 (Total Current Assets 985.3m - Total Current Liabilities 611.1m) / Total Assets 1.10b |
| B: -0.91 (Retained Earnings -998.0m / Total Assets 1.10b) |
| C: -0.00 (EBIT TTM -440.0k / Avg Total Assets 897.5m) |
| D: -1.06 (Book Value of Equity -997.8m / Total Liabilities 940.7m) |
| Altman-Z'' Score: -1.84 = D |
Beneish M -3.20
| DSRI: 1.07 (Receivables 219.8m/138.9m, Revenue 3.64b/2.47b) |
| GMI: 0.84 (GM 12.42% / 10.45%) |
| AQI: 0.59 (AQ_t 0.04 / AQ_t-1 0.07) |
| SGI: 1.47 (Revenue 3.64b / 2.47b) |
| TATA: -0.18 (NI -20.8m - CFO 181.6m) / TA 1.10b) |
| Beneish M-Score: -3.20 (Cap -4..+1) = AA |
What is the price of ALHC shares?
As of February 09, 2026, the stock is trading at USD 21.75 with a total of 2,111,510 shares traded.
Over the past week, the price has changed by -3.97%, over one month by +3.82%, over three months by +32.78% and over the past year by +50.73%.
Over the past week, the price has changed by -3.97%, over one month by +3.82%, over three months by +32.78% and over the past year by +50.73%.
Is ALHC a buy, sell or hold?
Alignment Healthcare has received a consensus analysts rating of 4.09.
Therefore, it is recommended to buy ALHC.
- StrongBuy: 6
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the ALHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.2 | 15.7% |
| Analysts Target Price | 25.2 | 15.7% |
| ValueRay Target Price | 22.7 | 4.4% |
ALHC Fundamental Data Overview February 07, 2026
P/E Forward = 250.0
P/S = 1.1635
P/B = 26.354
Revenue TTM = 3.64b USD
EBIT TTM = -440.0k USD
EBITDA TTM = 29.0m USD
Long Term Debt = 322.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.21m USD (from shortTermDebt, last fiscal year)
Debt = 329.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -288.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.92b USD (4.23b + Debt 329.7m - CCE 644.1m)
Interest Coverage Ratio = -0.03 (Ebit TTM -440.0k / Interest Expense TTM 17.3m)
EV/FCF = 22.74x (Enterprise Value 3.92b / FCF TTM 172.3m)
FCF Yield = 4.40% (FCF TTM 172.3m / Enterprise Value 3.92b)
FCF Margin = 4.74% (FCF TTM 172.3m / Revenue TTM 3.64b)
Net Margin = -0.57% (Net Income TTM -20.8m / Revenue TTM 3.64b)
Gross Margin = 12.42% ((Revenue TTM 3.64b - Cost of Revenue TTM 3.19b) / Revenue TTM)
Gross Margin QoQ = 12.65% (prev 13.15%)
Tobins Q-Ratio = 3.55 (Enterprise Value 3.92b / Total Assets 1.10b)
Interest Expense / Debt = 1.20% (Interest Expense 3.95m / Debt 329.7m)
Taxrate = 0.05% (2000 / 3.73m)
NOPAT = -439.8k (EBIT -440.0k * (1 - 0.05%)) [loss with tax shield]
Current Ratio = 1.61 (Total Current Assets 985.3m / Total Current Liabilities 611.1m)
Debt / Equity = 2.04 (Debt 329.7m / totalStockholderEquity, last quarter 161.9m)
Debt / EBITDA = -9.94 (Net Debt -288.4m / EBITDA 29.0m)
Debt / FCF = -1.67 (Net Debt -288.4m / FCF TTM 172.3m)
Total Stockholder Equity = 127.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.32% (Net Income -20.8m / Total Assets 1.10b)
RoE = -16.29% (Net Income TTM -20.8m / Total Stockholder Equity 127.7m)
RoCE = -0.10% (EBIT -440.0k / Capital Employed (Equity 127.7m + L.T.Debt 322.7m))
RoIC = -0.10% (negative operating profit) (NOPAT -439.8k / Invested Capital 449.8m)
WACC = 5.85% (E(4.23b)/V(4.56b) * Re(6.21%) + D(329.7m)/V(4.56b) * Rd(1.20%) * (1-Tc(0.00)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 5.33%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈172.3m ; Y1≈113.1m ; Y5≈51.6m
Fair Price DCF = 9.66 (EV 1.64b - Net Debt -288.4m = Equity 1.93b / Shares 200.1m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 71.24 | EPS CAGR: 38.96% | SUE: 1.92 | # QB: 4
Revenue Correlation: 97.98 | Revenue CAGR: 37.84% | SUE: 0.92 | # QB: 10
EPS next Quarter (2026-03-31): EPS=0.13 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.41 | Chg30d=+0.005 | Revisions Net=+2 | Growth EPS=+77.4% | Growth Revenue=+32.4%
P/S = 1.1635
P/B = 26.354
Revenue TTM = 3.64b USD
EBIT TTM = -440.0k USD
EBITDA TTM = 29.0m USD
Long Term Debt = 322.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.21m USD (from shortTermDebt, last fiscal year)
Debt = 329.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -288.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.92b USD (4.23b + Debt 329.7m - CCE 644.1m)
Interest Coverage Ratio = -0.03 (Ebit TTM -440.0k / Interest Expense TTM 17.3m)
EV/FCF = 22.74x (Enterprise Value 3.92b / FCF TTM 172.3m)
FCF Yield = 4.40% (FCF TTM 172.3m / Enterprise Value 3.92b)
FCF Margin = 4.74% (FCF TTM 172.3m / Revenue TTM 3.64b)
Net Margin = -0.57% (Net Income TTM -20.8m / Revenue TTM 3.64b)
Gross Margin = 12.42% ((Revenue TTM 3.64b - Cost of Revenue TTM 3.19b) / Revenue TTM)
Gross Margin QoQ = 12.65% (prev 13.15%)
Tobins Q-Ratio = 3.55 (Enterprise Value 3.92b / Total Assets 1.10b)
Interest Expense / Debt = 1.20% (Interest Expense 3.95m / Debt 329.7m)
Taxrate = 0.05% (2000 / 3.73m)
NOPAT = -439.8k (EBIT -440.0k * (1 - 0.05%)) [loss with tax shield]
Current Ratio = 1.61 (Total Current Assets 985.3m / Total Current Liabilities 611.1m)
Debt / Equity = 2.04 (Debt 329.7m / totalStockholderEquity, last quarter 161.9m)
Debt / EBITDA = -9.94 (Net Debt -288.4m / EBITDA 29.0m)
Debt / FCF = -1.67 (Net Debt -288.4m / FCF TTM 172.3m)
Total Stockholder Equity = 127.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.32% (Net Income -20.8m / Total Assets 1.10b)
RoE = -16.29% (Net Income TTM -20.8m / Total Stockholder Equity 127.7m)
RoCE = -0.10% (EBIT -440.0k / Capital Employed (Equity 127.7m + L.T.Debt 322.7m))
RoIC = -0.10% (negative operating profit) (NOPAT -439.8k / Invested Capital 449.8m)
WACC = 5.85% (E(4.23b)/V(4.56b) * Re(6.21%) + D(329.7m)/V(4.56b) * Rd(1.20%) * (1-Tc(0.00)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 5.33%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈172.3m ; Y1≈113.1m ; Y5≈51.6m
Fair Price DCF = 9.66 (EV 1.64b - Net Debt -288.4m = Equity 1.93b / Shares 200.1m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 71.24 | EPS CAGR: 38.96% | SUE: 1.92 | # QB: 4
Revenue Correlation: 97.98 | Revenue CAGR: 37.84% | SUE: 0.92 | # QB: 10
EPS next Quarter (2026-03-31): EPS=0.13 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.41 | Chg30d=+0.005 | Revisions Net=+2 | Growth EPS=+77.4% | Growth Revenue=+32.4%